Placeholder Banner

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

July 9, 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD:

2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from the likes of Merck (MRK) and Amgen (AMGN).  Its most advanced product candidate, Rolapitant, is in Phase II trials for chemotherapy-induced nausea and vomiting.  There have been seven U.S. IPOs thus far into 2012:

IPOs June 2012

3. FDA approvals: Three more approvals came in June, bringing the 2012 total to 14. Arena Pharmaceuticals’ (ARNA) weight-loss drug Belviq became the first new treatment for obesity in 13 years when it was approved by the FDA on the company’s second attempt.  Astellas’ overactive bladder drug Mybetriq was also approved in June, as was Roche’s anti-Her-2 antibody Perjeta:

                    Green =  biologic, (no color = small molecule)